Time to Response (TTR) and Early Tumor Shrinkage (ETS) in Recurrent Glioblastoma Patients Treated with Bevacizumab: an Exploratory Analysis of the Prospective Randomized AVAREG (ML25739) Phase II Study.
Annals of Oncology（2015）
Key words
Glioblastoma,Tumor Heterogeneity
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined